Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | MME | P08473 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | ACE | P12821 | 1/20 | 0.35 |
| ▸ | CPA1 | P15085 | 1/20 | 0.35 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | TYR | P14679 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | FAAH | O00519 | 2/20 | 0.32 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1491961 | 1.00 | TSHR (0.35) | TSHRMMERAB9AACECPA1 | |
| SCHEMBL35620 | 1.00 | TSHR (0.35) | TSHRMMERAB9AACECPA1 | |
| SCHEMBL2193000 | 0.84 | ECE1 (0.36) | TSHRMMEACECPA1ACE2 | |
| SCHEMBL15890229 | 0.80 | — | — | |
| SCHEMBL4443801 | 0.79 | TSHR (0.32) | TSHRALDH1A1 | |
| SCHEMBL14739662 | 0.78 | — | — | |
| SCHEMBL8869145 | 0.76 | CASP1 (0.43) | ALDH1A1MAPTTYR | |
| SCHEMBL991835 | 0.76 | CASP1 (0.43) | ALDH1A1MAPTTYR | |
| SCHEMBL10882651 | 0.76 | CASP1 (0.43) | ALDH1A1MAPTTYR | |
| SCHEMBL28173180 | 0.75 | LMNA (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 177 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3430448-B2 | METHOD OF MANUFACTURING SILICONE HYDROGEL CONTACT LENSES HAVING REDUCED RATES OF EVAPORATION | COOPERVISION INT LTD (GB) | 2025-07-23 | — | — | EP | claimed |
| EP-2342588-B9 | IONIC SILICONE HYDROGELS HAVING IMPROVED HYDROLYTIC STABILITY | JOHNSON & JOHNSON VISION CARE (US) | 2024-10-02 | — | — | EP | claimed |
| EP-2342588-B1 | IONIC SILICONE HYDROGELS HAVING IMPROVED HYDROLYTIC STABILITY | JOHNSON & JOHNSON VISION CARE (US) | 2024-07-03 | — | — | EP | claimed |
| EP-3430448-B1 | METHOD OF MANUFACTURING SILICONE HYDROGEL CONTACT LENSES HAVING REDUCED RATES OF EVAPORATION | COOPERVISION INT HOLDING CO LP (BB) | 2019-10-02 | — | — | EP | claimed |
| US-9260544-B2 | Ionic silicone hydrogels having improved hydrolytic stability | JOHNSON & JOHNSON VISION CARE, INC. (US) | 2016-02-16 | — | — | US | claimed |
| US-9101667-B2 | Ionic silicone hydrogels comprising pharmaceutical and/or neuticeutical components and having improved hydrolytic stability | JOHNSON & JOHNSON VISION CARE, INC. (US) | 2015-08-11 | — | — | US | claimed |
| EP-2855544-A2 | POLYMERS AND NANOGEL MATERIALS AND METHODS FOR MAKING AND USING THE SAME | Johnson & Johnson Vision Care Inc. (US) | 2015-04-08 | — | — | EP | claimed |
| US-20140329859-A1 | IONIC SILICONE HYDROGELS COMPRISING PHARMACEUTICAL AND/OR NEUTICEUTICAL COMPONENTS AND HAVING IMPROVED HYDROLYTIC STABILITY | JOHNSON & JOHNSON VISION CARE (US) | 2014-11-06 | — | — | US | claimed |
| US-20140296440-A1 | IONIC SILICONE HYDROGELS HAVING IMPROVED HYDROLYTIC STABILITY | JOHNSON & JOHNSON VISION CARE (US) | 2014-10-02 | — | — | US | claimed |
| US-8815972-B2 | Ionic silicone hydrogels having improved hydrolytic stability | JOHNSON & JOHNSON VISION CARE, INC. (US) | 2014-08-26 | — | — | US | claimed |
| JP-2011502198-A | — | — | 2011-01-20 | — | — | JP | claimed |
| US-20100249356-A1 | IONIC SILICONE HYDROGELS HAVING IMPROVED HYDROLYTIC STABILITY | JOHNSON & JOHNSON VISION CARE, INC. | 2010-09-30 | — | — | US | claimed |
| EP-2207825-A1 | PROCESS FOR FORMING RANDOM (METH)ACRYLATE CONTAINING PREPOLYMERS | Johnson & Johnson Vision Care, Inc. (US) | 2010-07-21 | — | — | EP | claimed |
| WO-2010039653-A1 | IONIC SILICONE HYDROGELS HAVING IMPROVED HYDROLYTIC STABILITY | JOHNSON & JOHNSON VISION CARE, INC. (US) | 2010-04-08 | — | — | WO | claimed |
| US-20090142485-A1 | Process for Making Biomedical Devices | LAI YU-CHIN | 2009-06-04 | — | — | US | claimed |
| WO-2009070443-A1 | PROCESS FOR MAKING BIOMEDICAL DEVICES | BAUSCH & LOMB INCORPORATED (US) | 2009-06-04 | — | — | WO | claimed |
| WO-2009058207-A1 | PROCESS FOR FORMING RANDOM (METH)ACRYLATE CONTAINING PREPOLYMERS | JOHNSON & JOHNSON VISION CARE, INC. (US) | 2009-05-07 | — | — | WO | claimed |
| US-20090111905-A1 | PROCESS FOR FORMING RANDOM (METH)ACRYLATE CONTAINING PREPOLYMERS | JOHNSON & JOHNSON VISION CARE, INC. | 2009-04-30 | — | — | US | claimed |
| EP-0441563-B1 | Detergent compositions containing vinyl carbamate compounds | UNILEVER PLC (GB) | 1995-05-24 | — | — | EP | claimed |
| EP-0441563-A2 | Detergent compositions containing vinyl carbamate compounds | UNILEVER PLC (GB) | 1991-08-14 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329859-A1 | IONIC SILICONE HYDROGELS COMPRISING PHARMACEUTICAL AND/OR NEUTICEUTICAL COMPONENTS AND HAVING IMPROVED HYDROLYTIC STABILITY | PIGS, PTMS, INHA | TSHR 1582/4885MME 2922/4885RAB9A 3810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.